Shares of pharmaceutical companies that make newer types of diabetes medication have fallen, following the U.S. Food and Drug Administration’s announcement that the agency is looking into potential health risks, according to a March 14 story in Bloomberg.
Among those drugs are Merck’s Januvia and Bristol-Myers Squibb’s Byetta.
The U.S. Food and Drug Administration has said the agency is seeking more information about recent findings linking the drugs to an increased risk ...
continue reading...